Odyssey Health, Inc. (ODYY) Responds to Growing Concerns

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
249
Odyssey Health, Inc. (ODYY) Responds to Growing Concerns About Concussion Head Injuries with Drug Device in Clinical Trial

- As awareness of the long-term hazards of concussive head injuries for young athletes has increased during the past decade, advocates and business enterprises have stepped up to improve coach responsiveness to players’ condition
- While efforts primarily focus on assessing injury, Odyssey Health Inc. is developing a product it hopes to become the first drug device with FDA approval for treating a concussed patient after injury
- Odyssey is enrolling patients in a Phase 1 human clinical trial after completing pre-clinical studies in laboratory animals
- The medical research company’s assets include treatments for patients who may have undiagnosed heart disease, patients choking on some type of obstruction lodged in their throats and patients dealing with a rare neurodegenerative disorder

Sports-related concussions have gained a growing degree of attention during the past decade, thanks largely to the activism of a junior high school football player severely injured during a game who continued to play despite a hard impact to the head he had experienced (https://nnw.fm/BZUzw ).

His story led to what has become known as the Lystedt Law, a series of head safety standards for youth athletes pioneered in Washington state and eventually adopted by all 50 states. Among professional athletes, concerns have been raised by players such as former Team U.S.A. soccer forward Bruce Murray’s, whose efforts to raise concussion awareness stem from head injuries he believes have left him with chronic traumatic encephalopathy (“CTE”), an incurable condition characterized by trouble with memory, problems organizing and planning simple activities, and changes in behavior, such as lack of motivation or having a short temper, but only truly diagnosable in deceased patients (https://nnw.fm/vIdgY ).

Former Denver Broncos football player Demaryius Thomas was one such athlete diagnosed with CTE after his death (https://nnw.fm/wXZk8 ).

Head impact injuries can affect athletes in a wide variety of sports, and numerous enterprises have manufactured devices designed to help measure injury among them. Head Impact Trauma Ltd. founder Euan Bowen, for example, was inspired by his rugby experience to create a headband and sensor system that measures cranial G-force but his product has been adopted by downhill mountain bike racers as well (https://nnw.fm/6IlWy ).

And a group of engineering students at Old Dominion University created an award-winning accelerometer designed to be affordable even for small schools interested in assessing head impacts in young players (https://nnw.fm/UfCnQ ).

Medical device innovator and biopharmaceutical product developer Odyssey Health (OTC: ODYY) is focusing on the concussion injury issue from the vantage point of treating individuals after they’ve been hurt. There is no medication approved by the U.S. Food and Drug Administration (“FDA”) at this point for treating specific concussion injuries, but Odyssey is preparing for human trials of a product it believes may fill that gap.

“We provide a clinical advantage in the marketplace,” CEO Michael Redmond told The RedChip Money Report(R) on Bloomberg TV last month. “We have a very unique new chemical entity intended to treat mild traumatic brain injury — the acute phase of a concussion. It’s a small device. It essentially goes and delivers a powderized drug through the upper chambers of the nasal cavity. The drug crosses the blood-brain barrier within five minutes. It spreads out throughout the brain within 30 minutes and reverses the effects of a concussion” (https://nnw.fm/uiNQt ).

The Phase 1 clinical trial is enrolling 48 patients and will follow completed preclinical lab animal testing.

Odyssey also is developing a prototype device for diagnosing heart disease and another for saving people choking on an obstruction that it hopes to have before the FDA for approval by year’s end.

For more information, visit the company’s website at www.OdysseyHealthInc.com.

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://nnw.fm/ODYY

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer


Odyssey Group Intl Inc (ODYY) Stock Research Links

ODYY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 249

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 272

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 231

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 349

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 207

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 432

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 211

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 367

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 285

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading

Top 5 Most Recently Viewed Articles

Elanco Secures FDA EUA for Credelio in Fighting NWS in Dogs

Updated Category News Views 275

Elanco's Innovative Step Against New World Screwworm Elanco Animal Health Incorporated (NYSE: ELAN) has achieved a significant milestone, receiving the first Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its product, Credelio™ (lotilaner), designed to treat infestations of New World Screwworm (NWS) in dogs. This groundbreaking...

Continue Reading
Hillary Ashton Sells Teradata Shares: Insights and Implications

Updated Category News Views 412

Hillary Ashton’s Sale of Teradata Shares: A Closer Look In an important insider transaction, Hillary Ashton, who is the Chief Product Officer at Teradata (TDC), recently sold 14,962 shares of the company's stock. This sale brought in a total of $411,903, as revealed in a recent SEC filing that highlights insider activity within the company. Currently, Teradata's stock...

Continue Reading
Legal Updates for Investors of Humana Inc. Amid Lawsuit

Updated Category News Views 158

Understanding the Ongoing Lawsuit Against Humana Inc. Investors focusing on the recent activities surrounding Humana Inc. (NYSE: HUM) should be aware of a significant lawsuit that has implications for individuals who acquired shares prior to July 2022. The Shareholders Foundation, Inc. has provided updates concerning the ongoing legal proceedings relevant to these...

Continue Reading
Empowering Local Job Seekers: The Trimborns of AtWork Tampa

Updated Category News Views 231

AtWork Opens New Storefront in Tampa, Florida AtWork, a prominent staffing franchise known for empowering job seekers and fostering company growth, has expanded its presence with a new location in Tampa. This strategic establishment at 8402 Laurel Fair Circle, Suite 101, stands across the Florida State Fairgrounds, ready to cater to the needs of the local workforce. Meet...

Continue Reading
Investor Claims Wall Street is Collapsing Cryptocurrency Values

Updated Category News Views 227

Investor Claims Wall Street is Collapsing Cryptocurrency Values Mike Alfred, a noted investor and proponent of Bitcoin, has raised significant concerns regarding potential manipulation of the cryptocurrency markets by major Wall Street players. He believes that these entities are actively working to drive down Bitcoin prices specifically to pressure companies like...

Continue Reading